Strategic News Watch — June 11, 2026
Takeda’s zasocitinib beat Bristol Myers’ Sotyktu head-to-head in psoriasis — a rare direct comparator win — while J&J’s Imaavy hit its primary endpoint in warm autoimmune hemolytic anemia and capital markets stayed open for a $320M cardiovascular biotech IPO.
Today’s top developments:
- Takeda’s zasocitinib outperformed Bristol Myers Squibb’s Sotyktu in a head-to-head psoriasis trial (BioPharma Dive)
- J&J’s Imaavy hit its primary endpoint in a pivotal trial for warm autoimmune hemolytic anemia (Fierce Pharma)
- Novartis’s del-brax RNA therapy, from its $12 billion Avidity acquisition, met its primary endpoint in a muscle-wasting disease study (BioPharma Dive)
- Kardigan plans a $320 million cardiovascular-focused IPO (Fierce Biotech)
What to Watch
- TYK2 competitive dynamics — Takeda’s head-to-head win over Bristol Myers could reshape commercial forecasts and trigger repositioning strategies across the oral immunology landscape.
- RNA conjugate platforms — Novartis’s early del-brax data will inform valuation expectations for other AOC-based assets and potential follow-on M&A in the space.
- ADC first-line expansion — Continued success in moving antibody-drug conjugates earlier into treatment paradigms may compress timelines for competing traditional chemotherapy regimens.
- Synthetic lethality deal structures — Watch for novel partnership models combining computational biology platforms with pharma genetic databases to accelerate target validation.
This brief highlights today’s top stories. Read the full June 11, 2026 edition → for all stories, source links, and analysis.
